Alexion Pharmaceuticals Inc. scored an important win for its defensive strategy on its all-important Soliris (eculizumab) franchise. The firm's next-generation long-acting C5 complement inhibitor, ALXN1210, performed as well as Soliris in a Phase III clinical trial in treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) dosed every eight weeks, versus every two-week dosing for Soliris.
Management said it is on track to submit regulatory filings for ALXN1210 in the US, Europe and Japan in the second half of 2018
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?